The company has licensing opportunities in the derivation of GMP HESC lines, RNAi and other differentiation control IPR. Potential collaborations with companies with relevant technology, R&D or market access capacity in the fields of immune-tolerogenesis and/or revascularisation particulalry in provision of scaffolds or transplantation would also be of interest. |